QUILT 2.023: A Phase 2, Open-Label, Randomized Study of N803, a Fusion Protein Activator of Natural Killer and T-Cells, in Combination With Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients With Advanced or Metastatic NSCLC.
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs ALT 803 (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms QUILT2.023
- Sponsors Altor BioScience Corporation
- 18 May 2018 Status changed from not yet recruiting to recruiting.
- 15 May 2018 Planned End Date changed from 3 Apr 2022 to 18 Apr 2022.
- 15 May 2018 Planned primary completion date changed from 3 Apr 2021 to 18 Apr 2021.